药康生物: 第二届监事会第十二次会议决议公告

Core Viewpoint - The supervisory board of Jiangsu Jicui Yaokang Biotechnology Co., Ltd. held its 12th meeting of the second supervisory board on August 21, 2025, to review and approve several key proposals related to the company's financial and operational status for the first half of 2025, ensuring compliance with legal and regulatory requirements [1][2]. Group 1: Meeting Overview - The meeting was convened with all three supervisory board members present, along with some senior management personnel [1]. - The meeting adhered to the relevant laws and regulations, as well as the company's articles of association [1]. Group 2: Financial Reporting - The supervisory board approved the company's 2025 half-year report and its summary, confirming that the report accurately reflects the company's financial status and operational results for the first half of 2025 [2]. - The board's vote on this matter was unanimous, with 3 votes in favor and no opposition or abstentions [2]. Group 3: Fund Management - The board approved a special report on the management and actual use of raised funds for the first half of 2025, confirming that the management of these funds is legal and compliant [2]. - The vote on this report also received unanimous approval, with 3 votes in favor [2]. Group 4: Profit Distribution - The supervisory board reviewed and approved the profit distribution plan for the first half of 2025, which considers the company's profitability, cash flow, and funding needs, ensuring reasonable returns for shareholders [3]. - This proposal is subject to further review by the shareholders' meeting [3]. Group 5: Governance Changes - The board approved the proposal to cancel the supervisory board and amend the company's articles of association, aiming to enhance the governance structure in line with the latest legal requirements [4]. - This decision also received unanimous support from the board members [4]. Group 6: Governance System Updates - The board approved the addition and revision of certain governance systems to improve the company's operational compliance and governance structure [4]. - The vote on these updates was also unanimous, with 3 votes in favor [4]. Group 7: Fund Usage - The supervisory board approved the use of the company's own funds to pay for part of the investment projects, with plans to replace these with raised funds, thereby improving fund usage efficiency [5]. - This proposal was unanimously approved by the board members [5].